The Changing Landscape of Maintenance Therapy in Newly Diagnosed Multiple Myeloma: A Systematic Review With Network Meta-Analysis of the European Myeloma Network (EMN).

Am J HematolJun 18, 2026 (epub)
Clinical ResearchHematologyOncology (Medical)Open access

Heinz Ludwig, Evangelos Terpos, Francesca Gay et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and network meta-analysis evaluated maintenance therapies for newly diagnosed multiple myeloma. It found that lenalidomide, proteasome inhibitors, and CD38 antibodies improved progression-free survival (PFS), with lenalidomide showing overall survival (OS) benefits in transplant-eligible patients. The daratumumab-lenalidomide regimen provided the greatest PFS advantage.

Key findings

  • Daratumumab-lenalidomide (DR) showed the greatest PFS benefit compared to observation.
  • Significant OS prolongation in transplant-eligible patients was observed with KR, DR, and lenalidomide alone.
  • CD38-directed therapy indicated a trend toward improved OS, unlike proteasome inhibitors.

Why it matters

Understanding the effectiveness of various maintenance therapies is crucial for optimizing treatment strategies in multiple myeloma, particularly in improving patient outcomes such as progression-free and overall survival.

Source

PubMed · PMID 42315477Free full text on PubMed Central

Published in Am J Hematol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Hematology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.